JP2015514726A - 肥満及び過体重の処置に用いるＳｏｒＣＳ１ - Google Patents

肥満及び過体重の処置に用いるＳｏｒＣＳ１ Download PDF

Info

Publication number
JP2015514726A
JP2015514726A JP2015506097A JP2015506097A JP2015514726A JP 2015514726 A JP2015514726 A JP 2015514726A JP 2015506097 A JP2015506097 A JP 2015506097A JP 2015506097 A JP2015506097 A JP 2015506097A JP 2015514726 A JP2015514726 A JP 2015514726A
Authority
JP
Japan
Prior art keywords
amino acid
acid residues
seq
polypeptide
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015506097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514726A5 (https=
Inventor
ピーザスン，カーアン−マリイ
ニュキヤー，アナス
フールサング クルビュ，マス
フールサング クルビュ，マス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of JP2015514726A publication Critical patent/JP2015514726A/ja
Publication of JP2015514726A5 publication Critical patent/JP2015514726A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015506097A 2012-04-17 2013-04-17 肥満及び過体重の処置に用いるＳｏｒＣＳ１ Pending JP2015514726A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270191 2012-04-17
DKPA201270191 2012-04-17
PCT/DK2013/050107 WO2013156031A2 (en) 2012-04-17 2013-04-17 SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT

Publications (2)

Publication Number Publication Date
JP2015514726A true JP2015514726A (ja) 2015-05-21
JP2015514726A5 JP2015514726A5 (https=) 2016-05-26

Family

ID=49384162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015506097A Pending JP2015514726A (ja) 2012-04-17 2013-04-17 肥満及び過体重の処置に用いるＳｏｒＣＳ１

Country Status (10)

Country Link
US (1) US20150166629A1 (https=)
EP (1) EP2874646A4 (https=)
JP (1) JP2015514726A (https=)
CN (1) CN104470532A (https=)
AU (1) AU2013248727A1 (https=)
CA (1) CA2870211A1 (https=)
HK (1) HK1208159A1 (https=)
IL (1) IL235066A0 (https=)
SG (1) SG11201406455YA (https=)
WO (1) WO2013156031A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136781B (zh) * 2015-08-13 2018-03-30 上海交通大学医学院附属瑞金医院 脂肪因子grem2作为药物靶点在治疗肥胖症药物中的应用
EP3666281A1 (en) * 2018-12-14 2020-06-17 Insusense ApS Compositions comprising sortilin-1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02503059A (ja) * 1988-01-25 1990-09-27 エグゾセル・インコーポレーテッド 抗グリコシルアルブミンモノクロナル抗体とそれらの抗体を産生するハイブリッド細胞株、およびその使用
JPH11507542A (ja) * 1995-06-13 1999-07-06 イムノ・アクチエンゲゼルシャフト プロトロンビン誘導体
JP2003519478A (ja) * 2000-01-10 2003-06-24 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
JP2010533130A (ja) * 2007-06-29 2010-10-21 インスティティ・パスツール 目的物質の送達用ペプチドベクターの製造のためのｖｈｈ抗体の使用及びその適用
WO2010142296A1 (en) * 2009-06-10 2010-12-16 Aarhus Universitet Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498476A1 (en) * 2002-09-09 2004-03-18 Wisconsin Alumni Research Foundation Type 2 diabetes susceptibility genes
RS60019B1 (sr) * 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02503059A (ja) * 1988-01-25 1990-09-27 エグゾセル・インコーポレーテッド 抗グリコシルアルブミンモノクロナル抗体とそれらの抗体を産生するハイブリッド細胞株、およびその使用
JPH11507542A (ja) * 1995-06-13 1999-07-06 イムノ・アクチエンゲゼルシャフト プロトロンビン誘導体
JP2003519478A (ja) * 2000-01-10 2003-06-24 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
JP2010533130A (ja) * 2007-06-29 2010-10-21 インスティティ・パスツール 目的物質の送達用ペプチドベクターの製造のためのｖｈｈ抗体の使用及びその適用
WO2010142296A1 (en) * 2009-06-10 2010-12-16 Aarhus Universitet Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto

Also Published As

Publication number Publication date
IL235066A0 (en) 2014-12-31
WO2013156031A3 (en) 2013-12-12
EP2874646A4 (en) 2016-07-06
EP2874646A2 (en) 2015-05-27
CN104470532A (zh) 2015-03-25
AU2013248727A1 (en) 2014-11-06
WO2013156031A2 (en) 2013-10-24
HK1208159A1 (en) 2016-02-26
US20150166629A1 (en) 2015-06-18
CA2870211A1 (en) 2013-10-24
SG11201406455YA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
JP5290966B2 (ja) 安定化されたインスリン様増殖因子ポリペプチド
US10172918B2 (en) SorCS1 for the treatment of obesity
BR112013033175A2 (pt) sequência de peptídeo, subsequência, composição, composição farmacêutica, molécula de ácido nucleico, vetor, célula transformada ou hospedeira, método de tratamento de um indivíduo, método para melhorar o metabolismo da glicose em um indivíduo e método para identificar uma sequência peptédica
CN101466399B (zh) 稳定的胰岛素样生长因子多肽
KR20160029731A (ko) 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
US20150299304A1 (en) Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease
US20170318057A1 (en) Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease
JP2015013872A (ja) 脂質動員特性を有する糖タンパク質およびその治療的使用法
JP2005502332A (ja) Ｇｍｇ−２ポリヌクレオチド及びポリペプチド並びにそれらの使用
US20160152710A1 (en) Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
JP2015514726A (ja) 肥満及び過体重の処置に用いるＳｏｒＣＳ１
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
HK1168283B (en) Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto
MXPA06009373A (en) Methods of treating obesity or diabetes using nt-4/5
HK1133822A (en) Stabilized insulin-like growth factor polypeptides
HK1126429B (en) Stabilized insulin-like growth factor polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170628